GSK, Teva Settle ‘Skinny Label’ Heart Medication Suit

By Editorial Team

GlaxoSmithKline (GSK) and Teva Pharmaceuticals have reached a settlement in a long-standing legal battle over a “skinny label” patent dispute concerning heart failure medication. The pharmaceutical giants informed a Delaware federal judge about the resolution and jointly requested the court to dismiss the case.

The dispute, which has spanned over a decade, centered around a patent related to a method of treatment for decreasing mortality resulting from congestive heart failure. The settlement marks the end of the litigation between the two companies.

The legal teams involved in the case included law firms Fish & Richardson, Goodwin Procter, and Shaw Keller. Notable companies mentioned in the proceedings were Hikma Pharmaceuticals PLC and Teva Pharmaceutical Industries Ltd.

The case was overseen by Judge Gregory B. Williams at the U.S. District Court for the District of Delaware. The settlement brings closure to a complex intellectual property and pharmaceutical litigation that has been closely watched by industry observers.